BioNTech SE Sponsored ADR $BNTX Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC grew its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 1,664.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 365,333 shares of the company’s stock after buying an additional 344,630 shares during the quarter. SG Americas Securities LLC owned 0.16% of BioNTech worth $34,780,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Financial Consulate Inc. bought a new stake in shares of BioNTech in the third quarter worth $36,000. Huntington National Bank boosted its stake in BioNTech by 1,266.7% during the 3rd quarter. Huntington National Bank now owns 410 shares of the company’s stock valued at $40,000 after acquiring an additional 380 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in BioNTech by 118.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after acquiring an additional 305 shares in the last quarter. GAMMA Investing LLC grew its holdings in BioNTech by 40.8% during the 3rd quarter. GAMMA Investing LLC now owns 784 shares of the company’s stock worth $77,000 after acquiring an additional 227 shares in the last quarter. Finally, Rakuten Securities Inc. increased its position in shares of BioNTech by 188.1% in the 3rd quarter. Rakuten Securities Inc. now owns 1,043 shares of the company’s stock worth $103,000 after purchasing an additional 681 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Trading Up 2.3%

NASDAQ BNTX opened at $88.77 on Thursday. BioNTech SE Sponsored ADR has a one year low of $79.52 and a one year high of $124.00. The company has a 50-day simple moving average of $104.54 and a 200-day simple moving average of $101.82. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.49 and a current ratio of 7.54. The firm has a market capitalization of $21.30 billion, a PE ratio of -16.94 and a beta of 1.51.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on BNTX shares. The Goldman Sachs Group restated a “buy” rating on shares of BioNTech in a research note on Wednesday, March 11th. Truist Financial raised BioNTech to a “strong-buy” rating in a report on Wednesday. BMO Capital Markets cut their price objective on BioNTech from $143.00 to $128.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 11th. Raymond James Financial reaffirmed an “outperform” rating on shares of BioNTech in a report on Tuesday, March 10th. Finally, Berenberg Bank reiterated a “buy” rating on shares of BioNTech in a research report on Friday, January 23rd. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $133.73.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.